Carl Zeiss Meditec ‘CZM’ released Q1 FY17 results ahead of our estimates as well as the market consensus. Revenue at CER increased by 5.4% (vs AV’s estimate: +4.8%), largely driven by positive growth momentum in the ophthalmic devices segment (+7.4% vs AV’s estimate: +6.2%; accounts for c.74% of Q1 17 revenue). Within the segment, robust development in the refractive laser business and market share gain in the surgical ophthalmology division were the key growth contrib
01 May 2017
Strong start to the year; Visumax launched in the US
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong start to the year; Visumax launched in the US
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
01 May 2017 -
Author:
Nishant Choudhary -
Pages:
3
Carl Zeiss Meditec ‘CZM’ released Q1 FY17 results ahead of our estimates as well as the market consensus. Revenue at CER increased by 5.4% (vs AV’s estimate: +4.8%), largely driven by positive growth momentum in the ophthalmic devices segment (+7.4% vs AV’s estimate: +6.2%; accounts for c.74% of Q1 17 revenue). Within the segment, robust development in the refractive laser business and market share gain in the surgical ophthalmology division were the key growth contrib